Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 239 for:    Itraconazole

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03843060
Recruitment Status : Completed
First Posted : February 15, 2019
Last Update Posted : April 22, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

Condition or disease Intervention/treatment Phase
Heart Failure With Preserved Ejection Fraction (HFpEF) Drug: AZD9977 Drug: Itraconazole Phase 1

Detailed Description:
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole. Two types of treatments (treatment period 1 and treatment period 2) will be administered in a fixed order separated by a washout period of 3 days or more. Treatment period 1 will be single dose of AZD9977 (Dose 1) administration, in the fed state, on Day 1 followed by at least 3 days washout period. For treatment period 2, Itraconazole will be administered daily (Dose 2) from Day 4 to Day 8 plus AZD9977 (Dose 1, fed state) will be administered as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Single Center Open-label, Non-randomized, Fixed Sequence Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of AZD9977 When Administered Alone and With Itraconazole
Actual Study Start Date : February 22, 2019
Actual Primary Completion Date : April 1, 2019
Actual Study Completion Date : April 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single AZD9977
During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
Drug: AZD9977
Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.

Experimental: Itraconazole + AZD9977
During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
Drug: Itraconazole
Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
Other Name: Sporanox




Primary Outcome Measures :
  1. Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977 [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) for AZD9977 [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  3. Maximum observed plasma concentration (Cmax) for AZD9977 [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole


Secondary Outcome Measures :
  1. Time to reach Maximum Observed Plasma Concentration (tMax) [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  2. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz) [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  3. Mean residence time of the unchanged drug in the systemic circulation from time zero to infinity (MRT) [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

  4. Terminal elimination rate constant (λz) [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  5. Apparent total body clearance of drug from plasmsa after extravascular administration (CL/F) [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  6. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) [ Time Frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose ]
    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

  7. Number of participants with adverse events (AEs) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess AEs as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  8. Number of participants with abnormal blood pressure (both systolic and diastolic blood pressure) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To measure BP as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. BP will be collected after the participants has rested in the supine position for at least 5 minutes.

  9. Number of participants with abnormal pulse rate [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To measure pulse rate as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. Pulse rate will be collected after the participants has rested in the supine position for at least 5 minutes.

  10. Number of participants with abnormal 12-lead Electrocardiograms (ECG) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To examine the safety and tolerability of AZD9977 in combination with itraconazole. 12-lead safety ECG will be obtained after the participant rested in the supine position for at least 10 minutes using the sites own ECG machines. The Principal Investigator (PI) will judge the overall interpretation as normal or abnormal and this evaluation will be reported in ClinBase. If abnormal, it will be further documented as to whether or not the abnormality is clinically significant by the PI.

  11. Number of participants with abnormal physical examination findings [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess any clinically significant abnormal physical examination findings as a variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. The complete physical examinations will include an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations will include an assessment of the general appearance, skin, abdomen, cardiovascular system and respiratory.

  12. Number of participants with abnormal laboratory assessments: Hematology- White blood cell (WBC) count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the white blood cell count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  13. Number of participnats with abnormal laboratory assessments: Hematology- Red blood cell (RBC) count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the red blood cell count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  14. Number of paticipants with abnormal laboratory assessments: Hematology - Hemoglobin (Hb) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the Hb as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  15. Number of participants with abnormal laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the HCT and reticulocyte absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  16. Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the MCH as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  17. Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular volume (MCV) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the MCV as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  18. Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the MCHC as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  19. Number of participants with abnormal laboratory assessments: Hematology- Neutrophils absolute count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the neutrophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  20. Number of participants with abnotmal laboratory assessments: Hematology- Lymphocytes absolute count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the Lymphocytes absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  21. Number of participants with abnormal laboratory assessments: Hematology- Monocytes absolute count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the Monocytes absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  22. Number of participants with abnormal laboratory assessments: Hematology- Eosinophils absolute count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the Eosinophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  23. Number of participants with abnormal laboratory assessments: Hematology- Basophils absolute count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the Basophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  24. Number of participants with abnormal laboratory assessments: Hematology- Platelets count [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the Platelets count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

  25. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the serum calcium, potassium, phosphate and sodium level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  26. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Liver enzymes [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the serum Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Gamma glutamyl transpeptidase (GGT) level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  27. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Albumin [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the albumin level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  28. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the CRP level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazol

  29. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the CK level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  30. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatinine [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the creatinine level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  31. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Glucose (fasting) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the fasting glucose level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  32. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- Uric acid [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the uric acid level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  33. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- BUN [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the BUN level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  34. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Total Bilirubin (TBL) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the TBL level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  35. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Indirect bilirubin [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the indirect bilirubin as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  36. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin I ((hsTnI) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the High-sensitivity troponin I ((hsTnI) as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  37. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

  38. Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Protein [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the urine protein level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. If urinalysis is positive for protein, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).

  39. Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Blood [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the urine blood level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).

  40. Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Glucose [ Time Frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks) ]
    To assess the urine glucose level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Provision of signed and dated, written informed consent prior to any study specific procedures.
  2. Healthy male and female participants of non-childbearing potential aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture.
  3. Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:

    1. Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels ≥40 mlU/ml.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

Exclusion Criteria:

  1. History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study..
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.

Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the PI including serum potassium > 5.0 mmol/L, serum hsTnI > 25.6 pg/mL, and NT-pro-BNP > 124 pg/mL.

5. Any clinically significant abnormal findings in vital signs as specified below and as judged by the PI at screening and on admission including:

  1. Systolic blood pressure (SBP) < 90 mmHg or > 140 mmHg.
  2. Diastolic blood pressure (DBP) < 50 mmHg or > 90 mmHg.
  3. HR < 45 or > 90 beats per minute (bpm). 6. Any clinically significant abnormalities on 12-lead ECG, as judged by the PI.

    7. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

    8. Known or suspected history of drug abuse in the last 12 months as judged by the Investigator.

    9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.

    10. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.

    11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.

    12. Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.

    13. Positive screen for drugs of abuse, cotinine or alcohol at screening or on each admission to the study center.

    14. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.

    15. Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life.

    16. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol in the last 12 months as judged by the PI.

    17. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.

    18. Participants who have previously received AZD9977. 19. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.

    20. Vulnerable participants , e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

    21. Participants with any special dietary restrictions such as participants that are lactose intolerant or are vegetarians/vegans.

    22. Drugs affecting CYP3A4 (itraconazole) should be refrained from use for 3 weeks prior to study commencement and thereafter until study completion.

    23. The following exclusion criterion is driven by contraindications from the proposed concomitant CYP3A4 (itraconazole) inhibitor medications: Itraconazole (Sporanox) capsules are contra-indicated in patients with known hypersensitivity to itraconazole or to any of the excipients.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03843060


Locations
Layout table for location information
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Ronald Goldwater Dr.

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03843060     History of Changes
Other Study ID Numbers: D6401C00003
First Posted: February 15, 2019    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by AstraZeneca:
Congestive heart failure
Healthy volunteers
Itraconazole
Drug-drug interaction
Pharmacokinetics
Open-label non-randomized
Additional relevant MeSH terms:
Layout table for MeSH terms
Itraconazole
Hydroxyitraconazole
Heart Failure
Heart Diseases
Cardiovascular Diseases
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors